TCTMD
@tctmd.bsky.social
Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at http://tctmd.com
The use of AI in cardiology has continued to advance this year, but clinicians are still questioning how it will improve their daily practice. Thomas Maddox talks about the biggest AI-related news of 2025 and where he thinks the field is headed in the future. www.tctmd.com/news/year-re...
Year in Review: Evidence Around AI in Cardiology Grows
As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more.
www.tctmd.com
December 30, 2025 at 4:02 PM
The use of AI in cardiology has continued to advance this year, but clinicians are still questioning how it will improve their daily practice. Thomas Maddox talks about the biggest AI-related news of 2025 and where he thinks the field is headed in the future. www.tctmd.com/news/year-re...
Top Cardiology News for 2025
Top Cardiology News for 2025
Top Cardiology News for 2025
cmacahilig@crf.org
Tue, 12/30/2025 - 09:05
2 minutes 18 seconds ago
The TCTMD journalists look back at the year's memorable moments—and take a few guesses at what's ahead.
www.tctmd.com
December 30, 2025 at 2:10 PM
Top Cardiology News for 2025
Year in Review: AI, Business Issues Dominate Cardiac Imaging
Year in Review: AI, Business Issues Dominate Cardiac Imaging
Year in Review: AI, Business Issues Dominate Cardiac Imaging
cmacahilig@crf.org
Mon, 12/29/2025 - 13:29
Yael L. Maxwell
The rise of photon-counting CT alongside a push for intravascular imaging during PCI also made headlines.
www.tctmd.com
December 30, 2025 at 2:05 PM
Year in Review: AI, Business Issues Dominate Cardiac Imaging
Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI
Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI
Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI
cmacahilig@crf.org
Mon, 12/29/2025 - 12:26
Yael L. Maxwell
New ACS guidelines made a splash alongside a range of imaging studies, as well.
www.tctmd.com
December 29, 2025 at 5:55 PM
Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI
FDA Approves Aficamten for Obstructive HCM
FDA Approves Aficamten for Obstructive HCM
FDA Approves Aficamten for Obstructive HCM
moriordan@crf.org
Mon, 12/29/2025 - 11:11
L.A. McKeown
The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
www.tctmd.com
December 29, 2025 at 4:20 PM
FDA Approves Aficamten for Obstructive HCM
Women's cardiovascular health, long underrepresented and misunderstood, saw an increase in interest this year. TCTMD has @americanheart.bsky.social president Stacey E. Rosen’s thoughts on the progress made in 2025 and as well as her top five noteworthy themes. www.tctmd.com/news/year-re...
Year in Review: Women’s Heart Health in the Spotlight
In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.
www.tctmd.com
December 29, 2025 at 3:10 PM
Women's cardiovascular health, long underrepresented and misunderstood, saw an increase in interest this year. TCTMD has @americanheart.bsky.social president Stacey E. Rosen’s thoughts on the progress made in 2025 and as well as her top five noteworthy themes. www.tctmd.com/news/year-re...
TCTMD’s Top 10 Most Popular Stories for December 2025
TCTMD’s Top 10 Most Popular Stories for December 2025
TCTMD’s Top 10 Most Popular Stories for December 2025
cmacahilig@crf.org
Tue, 12/23/2025 - 15:23
Michael O'Riordan
CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.
www.tctmd.com
December 29, 2025 at 2:01 PM
TCTMD’s Top 10 Most Popular Stories for December 2025
The large, newly published SURPASS-CVOT trial found that tirzepatide provides comparable CVD benefits compared with dulaglutide for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Read more here: www.tctmd.com/news/surpass...
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and atherosclerotic cardiovascular disease.
www.tctmd.com
December 28, 2025 at 2:05 PM
The large, newly published SURPASS-CVOT trial found that tirzepatide provides comparable CVD benefits compared with dulaglutide for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Read more here: www.tctmd.com/news/surpass...
The use of a single-pill combination therapy containing two or more antihypertensive agents may effectively manage blood pressure and greatly reduce cardiovascular events, according to a scientific statement from the @americanheart.bsky.social More here: www.tctmd.com/news/aha-hig...
AHA Highlights Single-Pill Combo Therapy for Hypertension
By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events
www.tctmd.com
December 27, 2025 at 1:56 PM
The use of a single-pill combination therapy containing two or more antihypertensive agents may effectively manage blood pressure and greatly reduce cardiovascular events, according to a scientific statement from the @americanheart.bsky.social More here: www.tctmd.com/news/aha-hig...
Aprocitentan, which targets the endothelin pathway, can safely lower blood pressure in patients with chronic kidney disease and resistant hypertension, based on a post-hoc analysis of the PRECISION trial. www.tctmd.com/news/aprocit...
Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION
Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.
www.tctmd.com
December 26, 2025 at 2:08 PM
Aprocitentan, which targets the endothelin pathway, can safely lower blood pressure in patients with chronic kidney disease and resistant hypertension, based on a post-hoc analysis of the PRECISION trial. www.tctmd.com/news/aprocit...
Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News
Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News
Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News
cmacahilig@crf.org
Tue, 12/23/2025 - 14:10
Todd Neale
New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.
www.tctmd.com
December 26, 2025 at 2:04 PM
Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News
Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News
Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News
Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News
cmacahilig@crf.org
Tue, 12/23/2025 - 14:02
Yael L. Maxwell
Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.
www.tctmd.com
December 26, 2025 at 2:04 PM
Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News
Angina patients who don't have ANOCA may not be at risk of worsening outcomes over a 15-year period, according to findings from a Danish study. This suggests that ANOCA alone doesn’t raise the risk of MI but only slightly increases the risk of ischemic stroke. www.tctmd.com/news/anoca-m...
ANOCA May Not Be as Risky as Feared: Danish Data
Angina patients with no obstructive CAD had no worse outcomes over 15 years, perhaps because they got the care they needed.
www.tctmd.com
December 25, 2025 at 12:43 PM
Angina patients who don't have ANOCA may not be at risk of worsening outcomes over a 15-year period, according to findings from a Danish study. This suggests that ANOCA alone doesn’t raise the risk of MI but only slightly increases the risk of ischemic stroke. www.tctmd.com/news/anoca-m...
Volt Pulsed-Field Ablation System Gains FDA Approval
Volt Pulsed-Field Ablation System Gains FDA Approval
Volt Pulsed-Field Ablation System Gains FDA Approval
cmacahilig@crf.org
Tue, 12/23/2025 - 14:28
Todd Neale
US physicians now have several PFA options to choose from.
www.tctmd.com
December 24, 2025 at 3:04 PM
Volt Pulsed-Field Ablation System Gains FDA Approval
Year in Review: Pulsed-Field Ablation Again Tops Heart Rhythm News
Year in Review: Pulsed-Field Ablation Again Tops Heart Rhythm News
Year in Review: Pulsed-Field Ablation Again Tops Heart Rhythm News
cmacahilig@crf.org
Mon, 12/22/2025 - 12:53
Todd Neale
Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.
www.tctmd.com
December 24, 2025 at 2:05 PM
Year in Review: Pulsed-Field Ablation Again Tops Heart Rhythm News
Year in Review: Top Prevention Stories of 2025
Year in Review: Top Prevention Stories of 2025
Year in Review: Top Prevention Stories of 2025
cmacahilig@crf.org
Mon, 12/22/2025 - 12:35
Michael O'Riordan
VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.
www.tctmd.com
December 24, 2025 at 2:05 PM
Year in Review: Top Prevention Stories of 2025
For adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia, the @fda.gov has approved the self-administered etripamil nasal spray. It's designed to rapidly stop episodes of paroxysmal supraventricular tachycardia and restore sinus rhythm. www.tctmd.com/news/etripam...
Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT
The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.
www.tctmd.com
December 24, 2025 at 1:06 PM
For adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia, the @fda.gov has approved the self-administered etripamil nasal spray. It's designed to rapidly stop episodes of paroxysmal supraventricular tachycardia and restore sinus rhythm. www.tctmd.com/news/etripam...
The 2024 ESC CCS Guidelines
The 2024 ESC CCS Guidelines
The 2024 ESC CCS Guidelines
cmacahilig@crf.org
Tue, 12/23/2025 - 15:11
2 minutes 34 seconds ago
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
www.tctmd.com
December 23, 2025 at 9:33 PM
The 2024 ESC CCS Guidelines
Rox Heart Radio: Cardiology's Biggest Moments in 2025
Rox Heart Radio: Cardiology's Biggest Moments in 2025
Rox Heart Radio: Cardiology's Biggest Moments in 2025
cmacahilig@crf.org
Tue, 12/23/2025 - 13:48
5 minutes 30 seconds ago
Roxana Mehran delves into the year's highlights with Michelle O'Donoghue.
www.tctmd.com
December 23, 2025 at 6:55 PM
Rox Heart Radio: Cardiology's Biggest Moments in 2025
FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement
FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement
FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement
cmacahilig@crf.org
Tue, 12/23/2025 - 12:22
Michael O'Riordan
This marks the first approval of a fully percutaneous TMVR device for patients with limited options.
www.tctmd.com
December 23, 2025 at 5:30 PM
FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement
December 2025 Dispatch for the CV Team
December 2025 Dispatch for the CV Team
December 2025 Dispatch for the CV Team
cmacahilig@crf.org
Tue, 12/23/2025 - 12:03
L.A. McKeown
This month: Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.
www.tctmd.com
December 23, 2025 at 5:16 PM
December 2025 Dispatch for the CV Team
Better LDL Control After STEMI Means Less Neoatherosclerosis
Better LDL Control After STEMI Means Less Neoatherosclerosis
Better LDL Control After STEMI Means Less Neoatherosclerosis
cmacahilig@crf.org
Tue, 12/23/2025 - 10:48
Yael L. Maxwell
The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.
www.tctmd.com
December 23, 2025 at 3:55 PM
Better LDL Control After STEMI Means Less Neoatherosclerosis
The @fda.gov has approved the use of lerodalcibep, alongside changes in diet and exercise, to reduce LDL cholesterol for adults with hypercholesterolemia. Read more here: www.tctmd.com/news/fda-app...
FDA Approves Lerodalcibep for Adults With Hypercholesterolemia
The third-generation PCSK9 inhibitor is self-administered monthly and can be kept at room temperature.
www.tctmd.com
December 23, 2025 at 3:24 PM
The @fda.gov has approved the use of lerodalcibep, alongside changes in diet and exercise, to reduce LDL cholesterol for adults with hypercholesterolemia. Read more here: www.tctmd.com/news/fda-app...
Year in Review: Evidence Around AI in Cardiology Grows
Year in Review: Evidence Around AI in Cardiology Grows
Year in Review: Evidence Around AI in Cardiology Grows
cmacahilig@crf.org
Mon, 12/22/2025 - 11:20
Todd Neale
As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more.
www.tctmd.com
December 23, 2025 at 2:03 PM
Year in Review: Evidence Around AI in Cardiology Grows
Year in Review: Women’s Heart Health in the Spotlight
Year in Review: Women’s Heart Health in the Spotlight
Year in Review: Women’s Heart Health in the Spotlight
cmacahilig@crf.org
Mon, 12/22/2025 - 11:01
Caitlin E. Cox
In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.
www.tctmd.com
December 23, 2025 at 2:03 PM
Year in Review: Women’s Heart Health in the Spotlight